NCT04974619 is a clinical trial of Online survey in HPV Vaccine, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Who is sponsoring NCT04974619?

NCT04974619 is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

What drugs are being tested in NCT04974619?

Interventions in NCT04974619: Online survey, Focus groups or Individual Interviews, Interviews.

What condition does NCT04974619 study?

NCT04974619 studies HPV Vaccine, HPV.

Is NCT04974619 still recruiting?

NCT04974619 is currently completed. Last updated 4 June 2024.

Are results published for NCT04974619?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-06-04 · How we verify

NCT04974619

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adaptation Of An HPV Education Resource To Promote HPV Vaccination

Completed Results posted Last updated 4 June 2024

What this trial tests

trial testing Online survey in HPV Vaccine in 155 participants. Completed in 30 August 2022.

Timeline

23 July 2021

Primary endpoint
30 August 2022

30 August 2022

Quick facts

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	155
Start date	23 July 2021
Primary completion	30 August 2022
Estimated completion	30 August 2022
Sites	2 locations across Puerto Rico, United States

Drugs / interventions tested

Online survey
Focus groups or Individual Interviews
Interviews

Conditions studied

HPV Vaccine — all drugs for HPV Vaccine →
HPV — all drugs for HPV →

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, any sex, with HPV Vaccine or HPV. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Part 1: HPV Vaccine Knowledge (Aim 1) Primary · Day 1

A scale consisting of 19 items (Score range 0-18) assessing general HPV knowledge and 9 items (Score range 0-9) assessing HPV vaccination-specific knowledge (modified from scales by Perez et al 2016 and Waller et al 2013, respectively), using a response scale consisting of True, False, and I don't know; higher scores mean higher knowledge.

HPV Knowledge (Scale Score range 0-18)

Group	Value	95% CI
Aim 1 Only: Online Survey Group	10.10	± 4.87

HPV Vaccination Knowledge Scale (Score range 0-9)

Group	Value	95% CI
Aim 1 Only: Online Survey Group	3.19	± 2.56

Part 1: HPV Vaccine Awareness (Aim 1) Primary · Day 1

A scale consisting of 2 items from the Health Information National Trends Survey (HINTS) 2018, with response options Yes or No; Positive responses mean higher awareness

Ever Heard of HPV?

Group	Value	95% CI
Aim 1 Only: Online Survey Group	21
Aim 1 Only: Online Survey Group	81

Ever Heard of HPV Vaccine?

Group	Value	95% CI
Aim 1 Only: Online Survey Group	45
Aim 1 Only: Online Survey Group	57

Part 1: HPV Vaccine Attitude (Aim 1) Primary · Day 1

A scale consisting of 8 items modified from the Carolina HPV Immunization Attitudes and Beliefs Scale (CHIAS); with a 5-point response scale ranging from strongly disagree to strongly agree; higher scores mean stronger attitudes. The possible scale score range = 8-40.

Group	Value	95% CI
Aim 1 Only: Online Survey Group	27.38	± 4.36

Part 1: HPV Vaccine Health Beliefs 1 (Aim 1) Primary · Day 1

Participants will complete scales; a. Perceived Risk 5 point scale from no chance to Certain I will get; higher scores mean higher perceived risk; b. Descriptive norms scale from 0% to 100%, higher score mean greater descriptive norms; c. Perceived norms 8 point scale ranging from strongly disagree to strongly agree, not applicable, higher scores mean stronger perceived norms; d. Perceived Barriers 3-point scale ranging from Not concerned at all to Very concerned, higher scores mean higher perceived barriers; e. Self-efficacy scale ranging from Strongly agree to Strongly Disagree; lower scores

Perceived Risk. 5 point scale with of Possible scale range 5-40

Group	Value	95% CI
Aim 1 Only: Online Survey Group	22.81	± 10.93

What percentage of peers do you think have received the HPV vaccine? Possible scale Range 0-100

Group	Value	95% CI
Aim 1 Only: Online Survey Group	20.01	± 22.78

What percentage of male peers do you think have received HPV vaccine? Possible scale Range 0-100

Group	Value	95% CI
Aim 1 Only: Online Survey Group	16.26	± 20.03

What percentage of gay/bisexual males do you think have received HPV vaccine? Possible Range 1-100

Group	Value	95% CI
Aim 1 Only: Online Survey Group	16.67	± 19.95

What percentage of female peers have received the HPV vaccine? Possible Scale Range 0-100

Group	Value	95% CI
Aim 1 Only: Online Survey Group	24.71	± 26.62

What percentage of gay/bisexual females received the HPV vaccine? Possible Scale Range 0-100

Group	Value	95% CI
Aim 1 Only: Online Survey Group	20.25	± 23.02

Perceived Norms. 8 items. Possible Score range 8-40

Group	Value	95% CI
Aim 1 Only: Online Survey Group	26.55	± 8.65

Perceived Barriers. 3 items. Possible score range 3-15.

Group	Value	95% CI
Aim 1 Only: Online Survey Group	7.19	± 3.01

Part 1: HPV Vaccine Health Beliefs 2 (Aim 1) Primary · Day 1

Count of participants who responded what they thought their perceived risk is contracting HPV. Questions range from Much below average, below average, average risk, above average risk, much above average risk, and I don't know.

Group	Value	95% CI
Aim 1 Only: Online Survey Group	27
Aim 1 Only: Online Survey Group	14
Aim 1 Only: Online Survey Group	29
Aim 1 Only: Online Survey Group	6

Part 1: HPV Vaccine Health Beliefs 3 (Aim 1) Primary · Day 1

Count of participants who responded within each category asking intention to get HPV vaccine among those unvaccinated, using a 7-point scale ranging from Very unlikely to Very likely, higher scores mean stronger intentions.

Intention to get information about the HPV vaccine

Group	Value	95% CI
Aim 1 Only: Online Survey Group	15
Aim 1 Only: Online Survey Group	2
Aim 1 Only: Online Survey Group	5
Aim 1 Only: Online Survey Group	13

Intention to obtain more than 1 shot in the next 12 months,

Group	Value	95% CI
Aim 1 Only: Online Survey Group	14
Aim 1 Only: Online Survey Group	5
Aim 1 Only: Online Survey Group	5
Aim 1 Only: Online Survey Group	27

Intention to get more than one dose in the future

Group	Value	95% CI
Aim 1 Only: Online Survey Group	12
Aim 1 Only: Online Survey Group	9
Aim 1 Only: Online Survey Group	4
Aim 1 Only: Online Survey Group	20

Part 1: HPV Vaccine Behaviors 1 (Aim 1) Primary · Day 1

Count of participants who responded within each category that assesses past receipt of the HPV vaccine (modified from Brewer et al., 2009 and Brewer et al., 2017). Responses were: Yes, No, I don't know.

Group	Value	95% CI
Aim 1 Only: Online Survey Group	0
Aim 1 Only: Online Survey Group	17
Aim 1 Only: Online Survey Group	6

Part 1: HPV Vaccine Behaviors 2 (Aim 1) Primary · Day 1

Count of participants that self reported number of shots received among vaccinated individuals. Items range from 1 shot to I don't know.

Group	Value	95% CI
Aim 1 Only: Online Survey Group	2
Aim 1 Only: Online Survey Group	1
Aim 1 Only: Online Survey Group	1
Aim 1 Only: Online Survey Group	1

Part 1: HPV Vaccine Educational Preferences 1 (Aim 1) Primary · Day 1

A scale developed by Christy (unpublished) assessing HPV vaccine education preferences. The survey question, "Who would you like to receive information from?". Options were Physician, Other healthcare provider (Nurse, Medical Assistant), Female peer, Male peer, Parent of teen, Parent of young adult, Someone who has survived an HPV-related Cancer Other. Participants marked all that applied.

Physicians

Group	Value	95% CI
Aim 1 Only: Online Survey Group	96

Other Healthcare Providers

Group	Value	95% CI
Aim 1 Only: Online Survey Group	59

Female Peer

Group	Value	95% CI
Aim 1 Only: Online Survey Group	8

Male Peer

Group	Value	95% CI
Aim 1 Only: Online Survey Group	19

Parent of Teen

Group	Value	95% CI
Aim 1 Only: Online Survey Group	3

Parent of Young Adult

Group	Value	95% CI
Aim 1 Only: Online Survey Group	4

HPV Cancer Survivor

Group	Value	95% CI
Aim 1 Only: Online Survey Group	40

Other

Group	Value	95% CI
Aim 1 Only: Online Survey Group	2

Part 1: HPV Vaccine Educational Preferences 2 (Aim 1) Primary · Day 1

Items developed by Christy (unpublished) assessing HPV vaccine education preferences. The survey question, "Best method for delivering education?". 1 being the best method and 8 being the worst method.

In Person

Group	Value	95% CI
Aim 1 Only: Online Survey Group	55
Aim 1 Only: Online Survey Group	6
Aim 1 Only: Online Survey Group	3
Aim 1 Only: Online Survey Group	7

Website

Group	Value	95% CI
Aim 1 Only: Online Survey Group	13
Aim 1 Only: Online Survey Group	26
Aim 1 Only: Online Survey Group	18
Aim 1 Only: Online Survey Group	14

Smart Phone App

Group	Value	95% CI
Aim 1 Only: Online Survey Group	1
Aim 1 Only: Online Survey Group	11
Aim 1 Only: Online Survey Group	17
Aim 1 Only: Online Survey Group	8

Online Webinar

Group	Value	95% CI
Aim 1 Only: Online Survey Group	2
Aim 1 Only: Online Survey Group	15
Aim 1 Only: Online Survey Group	14
Aim 1 Only: Online Survey Group	25

Text Message

Group	Value	95% CI
Aim 1 Only: Online Survey Group	6
Aim 1 Only: Online Survey Group	10
Aim 1 Only: Online Survey Group	13
Aim 1 Only: Online Survey Group	12

Printed Booklet

Group	Value	95% CI
Aim 1 Only: Online Survey Group	2
Aim 1 Only: Online Survey Group	13
Aim 1 Only: Online Survey Group	7
Aim 1 Only: Online Survey Group	9

Social Media Platform

Group	Value	95% CI
Aim 1 Only: Online Survey Group	13
Aim 1 Only: Online Survey Group	10
Aim 1 Only: Online Survey Group	16
Aim 1 Only: Online Survey Group	16

Healthcare System Portal

Group	Value	95% CI
Aim 1 Only: Online Survey Group	10
Aim 1 Only: Online Survey Group	11
Aim 1 Only: Online Survey Group	14
Aim 1 Only: Online Survey Group	11

Part 1: HPV Vaccine Educational Preferences 3 (Aim 1) Primary · Day 1

An item developed by Christy (unpublished) assessing HPV vaccine education preferences. The survey question, "What age would it be most helpful to for a person to receive educational information?"

Ages 9-10

Group	Value	95% CI
Aim 1 Only: Online Survey Group	89
Aim 1 Only: Online Survey Group	13

Ages 11-14

Group	Value	95% CI
Aim 1 Only: Online Survey Group	74
Aim 1 Only: Online Survey Group	28

Ages 15-17

Group	Value	95% CI
Aim 1 Only: Online Survey Group	49
Aim 1 Only: Online Survey Group	53

Ages 18-22

Group	Value	95% CI
Aim 1 Only: Online Survey Group	50
Aim 1 Only: Online Survey Group	52

Ages 23-30

Group	Value	95% CI
Aim 1 Only: Online Survey Group	70
Aim 1 Only: Online Survey Group	32

Ages 30-45

Group	Value	95% CI
Aim 1 Only: Online Survey Group	84
Aim 1 Only: Online Survey Group	18

I Do Not Think So

Group	Value	95% CI
Aim 1 Only: Online Survey Group	102
Aim 1 Only: Online Survey Group	0

Part 2: Facilitators and Barriers to Intervention Implementation (Aim 2) Primary · Day 1

Number of participants who consented and participated in individual interviews.

Group	Value	95% CI
Aim 2 Only: Interview Group	20

Sponsor's own description

The purpose of the study is to assess Human Papillomavirus (HPV) and HPV vaccination knowledge, awareness, attitudes, health beliefs, and behaviors as well as educational preferences for learning more about HPV and HPV vaccination and to receive feedback on and adapt HPV educational materials for Young Latino Men who have Sex with Men (YLMSM).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Online survey

Trials testing the same drug.

NCT07460778 — Development of Serious Games for Rehabilitation: a Delphi Study · NA · recruiting
NCT04788004 — Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse · active not recruiting
NCT04659473 — Spanish Survey on Third Wave of COVID-19 · unknown
NCT04645979 — A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic R · completed
NCT03921476 — Acne and Mood: Impact of Treatment on Depression, Anxiety, and Sexual Function · withdrawn

Other recruiting trials for HPV Vaccine

Currently open trials in the same condition.

NCT06831929 — HPV Ends Here: Increasing Uptake of the HPV Vaccine · NA · recruiting
NCT06227689 — Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China · NA · recruiting
NCT05291871 — Immunogenicity of Fractional Dose of the HPV Vaccines · Phase 4 · active not recruiting
NCT04235257 — Intradermal, Fractional Dose of HPV Vaccines: · Phase 4 · active not recruiting

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04974619 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 4 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04974619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing